Katz Joel S, Frankel Hyman, Ma Tracy, Zagzag David, Liechty Benjamin, Zeev Bruria Ben, Tzadok Michal, Devinsky Orrin, Weiner Howard L, Roth Jonathan
Department of Neurosurgery, OhioHealth, Grant and Riverside Medical Center, 111 S Grant Avenue, Columbus, OH, 43215, USA.
Department of Neurosurgery, Division of Pediatric Neurosurgery, NYU Langone Medical Center, 550 First Avenue, New York, NY, 10016, USA.
Childs Nerv Syst. 2017 Apr;33(4):601-607. doi: 10.1007/s00381-017-3335-z. Epub 2017 Jan 10.
Tuberous sclerosis is associated with three central nervous system pathologies: cortical/subcortical tubers, subependymal nodules (SENs), and subependymal giant cell astrocytomas (SEGAs). Tubers are associated with epilepsy, which is often medication-resistant and often leads to resective surgery. Recently, mammalian target of rapamycin inhibitors (mTORi) have been shown to be effective reducing seizure burden in some patients with tuberous sclerosis complex (TSC)-related refractory epilepsy. mTORi have also been shown to be an alternative for surgery treating SEGAs. We describe several cases of resected tubers that contained SEGA tissue without an intraventricular SEGA.
After institutional review board (IRB) protocol approval, we retrospectively reviewed the surgical-pathological data for all TSC patients who underwent cortical resections for treatment of refractory epilepsy at NYU Langone Medical Center and Tel Aviv Medical Center between 2003 and 2013. Data included demographics, epilepsy type, MRI characteristics, epilepsy outcome, and histopathological staining.
We reviewed cortical resections from 75 patients with complete pathological studies. In three patients, cortical lesions demonstrated histopathological findings consistent with a SEGA within the resected tuber tissue, with no intraventricular SEGA. All lesions were cortically based and none had any intraventricular extension. No patient had been treated before surgery with an mTORi. Two of the three patients remain Engel grade I-II. All lesions stained positive for glial fibrillary acidic protein (GFAP), synaptophysin, and neuronal nuclear antigen (NeuN).
This is the first description of cortical tubers harboring SEGA tissue. This observation though preliminary may suggest a subgroup of patients with intractable epilepsy in whom mTORi may be considered before surgical intervention.
结节性硬化症与三种中枢神经系统病变相关:皮质/皮质下结节、室管膜下结节(SENs)和室管膜下巨细胞星形细胞瘤(SEGAs)。结节与癫痫相关,癫痫通常对药物治疗耐药,常需进行切除性手术。最近,雷帕霉素哺乳动物靶点抑制剂(mTORi)已被证明可有效减轻部分结节性硬化症复合体(TSC)相关难治性癫痫患者的癫痫负担。mTORi也已被证明是治疗SEGAs的手术替代方法。我们描述了几例切除的含有SEGA组织但无脑室内SEGA的结节病例。
经机构审查委员会(IRB)方案批准后,我们回顾性分析了2003年至2013年期间在纽约大学朗格尼医学中心和特拉维夫医学中心因难治性癫痫接受皮质切除术的所有TSC患者的手术病理数据。数据包括人口统计学、癫痫类型、MRI特征、癫痫结局和组织病理学染色。
我们回顾了75例有完整病理研究的皮质切除术病例。在3例患者中,皮质病变在切除的结节组织中显示出与SEGA一致的组织病理学表现,无脑室内SEGA。所有病变均位于皮质,无任何脑室内延伸。术前所有患者均未接受mTORi治疗。3例患者中有2例仍为恩格尔I-II级。所有病变胶质纤维酸性蛋白(GFAP)、突触素和神经元核抗原(NeuN)染色均为阳性。
这是首次对含有SEGA组织的皮质结节进行描述。这一观察结果虽然初步,但可能提示在手术干预前可考虑使用mTORi的难治性癫痫患者亚组。